Test Price
2,800 AED✅ Home Collection Available
GSDME (DFNA5) Gene NGS Sequencing – Autosomal Dominant Deafness Type 5 | 2,800 AED | Genetic Hearing Loss Diagnosis
Executive Summary & Core Metrics
Comprehensive Genetic Analysis for Hereditary Hearing Loss
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The GSDME (DFNA5) gene NGS test detects pathogenic variants associated with autosomal dominant non-syndromic hearing loss (DFNA5), enabling precise molecular diagnosis of hereditary deafness. This high-sensitivity analysis is performed on peripheral whole blood or buccal swab specimens using next-generation sequencing with orthogonal Sanger confirmation.
| Feature | Our GSDME NGS Test | Closest Alternative (Single-Gene Sanger) |
|---|---|---|
| Precision | 99.9% Analytical Sensitivity & Specificity | 95–98% for targeted regions |
| Method | Next-Generation Sequencing (NGS) + Sanger Confirmation | Conventional Sanger Sequencing |
| Turnaround Time | 3 to 4 Weeks | 6–8 Weeks |
| Coverage | Full coding region & splice sites | Sequential exon-by-exon |
Physician Insight & Safety Protocols
“Interpreting genetic hearing loss requires both molecular precision and a deep understanding of family context. Our NGS approach for GSDME ensures every variant is rigorously evaluated against clinical audiological data. This test provides a definitive answer for inherited deafness patterns but should always be accompanied by genetic counselling.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory – Test Limitations and Clinical Context
This genetic test is a diagnostic tool and does not replace a comprehensive otologic evaluation. Results should be interpreted in conjunction with pure-tone audiometry, tympanometry, and family pedigree analysis. Do not alter any ongoing treatment or medication without consulting your physician.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: This test is not intended for prenatal diagnosis without prior genetic counselling. It should not be used as the sole investigation in non-genetic hearing loss (e.g., ototoxic drug exposure, acute noise trauma) unless a hereditary component is strongly suspected.
- Emergency Red Flags: If you experience sudden hearing loss, severe vertigo, facial weakness, or tinnitus, seek immediate emergency care. These symptoms may indicate acute otologic emergencies unrelated to genetic testing.
- Minors require parental consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. What is the GSDME (DFNA5) gene deafness test and who should consider it?
This NGS-based test identifies mutations in the GSDME gene responsible for autosomal dominant non-syndromic hearing loss, aiding early diagnosis and family planning. It is recommended for individuals with progressive sensorineural hearing loss and a strong family history of deafness, as well as for asymptomatic at-risk relatives seeking clarity.
2. How accurate is this genetic test and what is the turnaround time?
With over 99.9% diagnostic sensitivity and confirmation via Sanger sequencing, results are provided within 3 to 4 weeks from sample receipt. Our ISO-certified laboratory uses the latest NGS technology and bioinformatics analysis pipelines to ensure reliable variant interpretation.
3. Are there any special preparation steps or risks associated with sample collection?
No fasting or medication adjustments are needed; a simple blood draw or buccal swab is collected by our certified phlebotomists without significant risk. The procedure is painless and takes only a few minutes; you can resume daily activities immediately.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted and processed under DHA oversight. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Our facility holds DHA License No. 1143 and is accredited under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | GSDME (DFNA5) Gene NGS Sequencing – Autosomal Dominant Deafness Type 5 |
| Price (AED) | 2,800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Buccal Swab / Saliva |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | H90.5 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians